Cargando…
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity
Tumor necrosis factor receptor superfamily member 7 (TNFRSF7, CD27), expressed primarily by T cells, and its ligand CD27L (TNFSF7, CD70) provide co-stimulatory signals that boost T cell activation, differentiation, and survival. Agonistic stimulation of CD27 is therefore a promising therapeutic conc...
Autores principales: | Thiemann, Meinolf, Richards, David M., Heinonen, Karl, Kluge, Michael, Marschall, Viola, Merz, Christian, Redondo Müller, Mauricio, Schnyder, Tim, Sefrin, Julian P., Sykora, Jaromir, Fricke, Harald, Gieffers, Christian, Hill, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160747/ https://www.ncbi.nlm.nih.gov/pubmed/30298117 http://dx.doi.org/10.3389/fonc.2018.00387 |
Ejemplares similares
-
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
por: Richards, David M., et al.
Publicado: (2019) -
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy
por: Frankish, Jamie, et al.
Publicado: (2023) -
Concepts for agonistic targeting of CD40 in immuno-oncology
por: Richards, David M., et al.
Publicado: (2019) -
Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro
por: Merz, Christian, et al.
Publicado: (2015) -
Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
por: Hanke, Nina, et al.
Publicado: (2019)